VC-Y705F+K685R-STAT3
(Plasmid
#203722)
-
PurposeExpresses the PTM-resistant, double mutant Y705F+K685R - STAT3 fused to the 158-238 fragment of Venus in mammalian cells
-
Depositing Lab
-
Sequence Information
Ordering
Item | Catalog # | Description | Quantity | Price (USD) | |
---|---|---|---|---|---|
Plasmid | 203722 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $85 |
Backbone
-
Vector backbonepcDNA 3.3 Topo
-
Backbone manufacturerLife Technologies
- Backbone size w/o insert (bp) 5440
-
Vector typeMammalian Expression
-
Selectable markersNeomycin (select with G418)
Growth in Bacteria
-
Bacterial Resistance(s)Ampicillin, 100 μg/mL
-
Growth Temperature37°C
-
Growth Strain(s)DH5alpha
-
Copy numberHigh Copy
Gene/Insert
-
Gene/Insert nameSTAT3 tagged with VC (aa 158-238)
-
Alt nameAPRF
-
SpeciesH. sapiens (human)
-
Insert Size (bp)2571
-
MutationY705F+K685R substitutions
-
Entrez GeneSTAT3 (a.k.a. ADMIO, ADMIO1, APRF, HIES)
- Promoter CMV
-
Tag
/ Fusion Protein
- VC (aa 158-238) for bimolecular fluorescence complementation assays (N terminal on insert)
Cloning Information
- Cloning method Unknown
- 5′ sequencing primer CMV-F (Common Sequencing Primers)
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Trademarks:
- Zeocin® is an InvivoGen trademark.
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
VC-Y705F+K685R-STAT3 was a gift from Federico Herrera (Addgene plasmid # 203722 ; http://n2t.net/addgene:203722 ; RRID:Addgene_203722) -
For your References section:
Asymmetric post-translational modifications regulate the nuclear translocation of STAT3 homodimers in response to leukemia inhibitory factor. Diallo M, Pimenta C, Murtinheira F, Martins-Alves D, Pinto FR, da Costa AA, Letra-Vilela R, Martin V, Rodriguez C, Rodrigues MS, Herrera F. Cell Oncol (Dordr). 2023 Dec 27. doi: 10.1007/s13402-023-00911-9. 10.1007/s13402-023-00911-9 PubMed 38150153